Articles by Matthew Galsky, MD
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
Drs. Galsky and Nizam spotlight a phase 3 study of disitamab vedotin for la/mUC that expresses HER2.
Drs. Matthew Galsky and Amanda Nizam break down the latest data subanalysis from the CheckMate 901 trial.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
The panel shares their hopes for the future of bladder cancer treatment.
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
The panel shares treatment sequencing decisions based on a few patient scenarios.
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
The panel shares lessons learned from the phase THOR study.
Bladder Panel Offers Insights on CheckMate 901 Study and Optimal Duration of Immunotherapy Treatment
The panel discusses the CheckMate 901 study results.
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
The panel discusses the "buzz" around the EV-302 study.
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
Matt Galsky continues his discussion on ctDNA in bladder cancer and covers topics such as candidate versus panel approaches.
Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.